LBPH Stock Price, Longboard Pharmaceuticals, . Quote, Chart

Market Summary

USD16.99-1.26

Market Closed

-6.90%

LBPH Stock Price

View Fullscreen

LBPH RSI Chart

LBPH Valuation

Market Cap

611.9M

Price/Earnings (Trailing)

-11.24

Price/Free Cashflow

-12.03

LBPH Price/Earnings (Trailing)

LBPH Profitability

Return on Equity

-132.99%

Return on Assets

-107.35%

Free Cashflow Yield

-8.31%

LBPH Fundamentals

LBPH Earnings

Earnings (TTM)

-54.4M

Earnings Growth (Yr)

-32.51%

Earnings Growth (Qtr)

-16.23%

Breaking Down LBPH Revenue

Last 7 days

-7.2%

Last 30 days

-17.0%

Last 90 days

-28.3%

Trailing 12 Months

141.3%

How does LBPH drawdown profile look like?

LBPH Financial Health

Current Ratio

5.14

LBPH Investor Care

Shares Dilution (1Y)

38.58%

Diluted EPS (TTM)

-2.38

Tracking the Latest Insider Buys and Sells of Longboard Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 08, 2024	kaye randall	acquired	-	-	17,920	cmo
Feb 08, 2024	roberts brandi	acquired	-	-	15,090	cfo
Jan 25, 2024	arena pharmaceuticals inc	sold	-96,479,600	24.25	-3,978,540	-
Mar 16, 2021	arena pharmaceuticals inc	acquired	-	-	138,000	-

Which funds bought or sold LBPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 05, 2024	GAMMA Investing LLC	new	-	1,555	1,555	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.69	399,425	4,742,190	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	147	103,644	165,210	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	3,467	46,690	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	reduced	-8.2	-43,000	9,812,000	-%
Feb 15, 2024	BARCLAYS PLC	added	668	113,000	129,000	-%
Feb 15, 2024	Legal & General Group Plc	unchanged	-	784	10,070	-%
Feb 14, 2024	MOORE CAPITAL MANAGEMENT, LP	sold off	-100	-254,248	-	-%
Feb 14, 2024	Prosight Management, LP	sold off	-100	-1,785,620	-	-%
Feb 14, 2024	Laurion Capital Management LP	reduced	-17.25	-15,101	132,117	-%

Are Funds Buying or Selling LBPH?

Are funds buying LBPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LBPH

No. of Funds

Unveiling Longboard Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	7.6%	1,626,982	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	3.8%	825,000	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	4.79%	1,027,679	SC 13G/A
Feb 13, 2024	prosight management, lp	0.0%	0	SC 13G/A
Feb 13, 2024	hbm healthcare investments (cayman) ltd.	0%	0	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 30, 2024	farallon capital partners, l.p.	5.5%	1,205,990	SC 13G/A
Jan 29, 2024	pfizer inc	0.00%	0	SC 13D/A
Jan 26, 2024	integrated core strategies (us) llc	0.0%	6,603	SC 13G/A

Recent SEC filings of Longboard Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	8-K	Current Report
Apr 12, 2024	ARS	ARS
Apr 12, 2024	DEF 14A	DEF 14A
Apr 12, 2024	DEFA14A	DEFA14A
Mar 28, 2024	PRE 14A	PRE 14A
Mar 26, 2024	8-K	Current Report
Mar 12, 2024	10-K	Annual Report
Mar 12, 2024	8-K	Current Report
Mar 12, 2024	S-3ASR	S-3ASR
Mar 12, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to Longboard Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.94	14.59	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.73	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.79	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.24	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

Longboard Pharmaceuticals, Inc. News

Latest updates

Longboard Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-13.9%	51.00	59.00	66.00	80.00	71.00	81.00	91.00	101	109	116	121	124	56.00
Current Assets	-13.9%	50.00	58.00	66.00	79.00	70.00	80.00	90.00	100	108	115	121	124	55.00
Cash Equivalents	-40.1%	14.00	24.00	20.00	25.00	11.00	19.00	28.00	35.00	66.00	75.00	91.00	121	55.00
Net PPE	-20.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Current Liabilities	45.6%	10.00	7.00	8.00	7.00	9.00	8.00	8.00	7.00	5.00	4.00	3.00	4.00	3.00
Shareholder's Equity	-21.4%	41.00	52.00	58.00	72.00	61.00	72.00	83.00	94.00	103	112	117	120	-
Retained Earnings	-12.0%	-140	-125	-112	-97.60	-86.10	-74.80	-63.20	-51.80	-42.20	-33.42	-27.10	-20.10	-14.40
Additional Paid-In Capital	2.1%	182	178	171	170	148	148	147	146	146	145	145	140	12.00
Shares Outstanding	3.1%	22.00	21.00	21.00	21.00	14.00	17.00	17.00	17.00	13.00	17.00	17.00	7.00	-
Float	-	-	-	148	-	-	-	52.00	-	-	-	117,500	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	17.0%	-11,028	-13,289	-13,454	-13,097	-9,671	-9,853	-8,514	-10,025	-5,675	-6,134	-5,150	-7,746	-1,459	-1,041	-903	-39.00
Share Based Compensation	0.5%	860	856	841	697	592	795	699	571	584	538	512	333	7,360	498	555	95.00
Cashflow From Investing	-113.3%	-1,561	11,749	7,962	6,083	2,145	882	1,193	-21,284	-	-	-	-	-	-	-	-
Cashflow From Financing	-49.4%	3,010	5,946	-125	21,360	-444	-	-	-	-	-2.00	3,172	73,281	-	-	-	39.00

LBPH Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 43,752	$ 34,638
General and administrative	13,007	10,160
Total operating expenses	56,759	44,798
Loss from operations	(56,759)	(44,798)
Interest income, net	2,405	837
Other expense	(68)	16
Net loss	$ (54,422)	$ (43,945)
Net loss per share, basic	$ (2.39)	$ (2.56)
Net loss per share, Diluted	$ (2.39)	$ (2.56)
Weighted-average shares outstanding, basic	22,726,325	17,150,907
Weighted-average shares outstanding, diluted	22,726,325	17,150,907
Comprehensive loss:
Net Income (Loss)	$ (54,422)	$ (43,945)
Unrealized gain (loss) on short-term investments	614	(528)
Comprehensive loss	$ (53,808)	$ (44,473)

LBPH Balance Sheet

2023-12-31

Condensed Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 14,331	$ 10,775
Short-Term Investments	34,167	56,814
Prepaid expenses and other current assets	1,723	2,249
Total current assets	50,221	69,838
Right-of-use assets	472	736
Property and equipment	4	9
Other long-term assets	0	33
Total assets	50,697	70,616
Current liabilities:
Accounts payable	1,001	1,310
Accrued research and development expenses	4,556	4,168
Accrued compensation and related expenses	3,374	2,438
Accrued other expenses	368	490
Right-of-use liabilities, current portion	475	358
Total current liabilities	9,774	8,764
Right-of-use liabilities, net of current portion	0	382
Commitments and contingencies (see Note 9)
Stockholders’ equity (deficit):
Preferred stock, value	0	0
Common stock, value	2	1
Additional paid-in-capital	181,563	148,303
Accumulated other comprehensive loss	(78)	(692)
Accumulated deficit	(140,564)	(86,142)
Total stockholders equity	40,923	61,470
Total liabilities and stockholders' equity	50,697	70,616
Non-Voting Common Stock [Member]
Stockholders’ equity (deficit):
Common stock, value	$ 0	$ 0

About Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

CEO	Mr. Kevin R. Lind
WEBSITE	longboardpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	32

Longboard Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Longboard Pharmaceuticals, Inc.? What does LBPH stand for in stocks?

LBPH is the stock ticker symbol of Longboard Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Longboard Pharmaceuticals, Inc. (LBPH)?

As of Wed Apr 17 2024, market cap of Longboard Pharmaceuticals, Inc. is 611.93 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LBPH stock?

You can check LBPH's fair value in chart for subscribers.

What is the fair value of LBPH stock?

You can check LBPH's fair value in chart for subscribers. The fair value of Longboard Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Longboard Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LBPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Longboard Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether LBPH is over valued or under valued. Whether Longboard Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Longboard Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LBPH.